Jade Biosciences (JBIO)

• Market cap: $1.24B
• 1 day: -0.51%
• 5 days: 12.39%
• 1 month: 55.41%
• 3 months: 64.03%
• 6 months: 180.78%
• Year to date: 77.47%
• 1 year: 149.06%
• 5 years: -96.86%
• 10 years: -96.86%
• Sector: Healthcare
• Industry: Biotechnology

About: Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.

Employees: 55